BobbyBellagio
Posted - 51 minutes from now
$HUMA If y’all knew what you were doing you wouldn’t have to take anyone’s word and this would be an equal debate instead of just entertainment
drizz
Posted - 21 minutes from now
$HUMA if it’s true that Laura bought shares today I think it’s significant in that she’s essentially signaling to the markets there has been nothing material disclosed by the fda - otherwise she’d be trading on material non public info which is a major no no
billackmansnan
Posted - 3 minutes from now
$HUMA here kitty kitty kitty
qtip04
Posted - 8 minutes ago
$HUMA they can't hold her down too long, it seems that shorts have returned some shares today, soon they will have a rude awakening. She's golden. As far as Brady it looks to me that he's done selling as some explanation issued and Laura put on her own cash to buy some shares. When the news comes she will go stupid.
Mnpois
Posted - 38 minutes ago
$HUMA will he sell again today?
STOCKRISING1
Posted - 1 hour ago
$HUMA only new Lowe’s daily. Let’s see other catchy words they’ll use. Approval: “incoming”, “any moment” and then after a rally “selll selll!” L. Nothing to see here.. rinse repeat
BobbyBellagio
Posted - 1 hour ago
$HUMA Y’all are exceptional and way better than me reading, digesting, and critically thinking about the new paper published.
Wish I had your guys critical thinking skills
zax0255
Posted - 1 hour ago
$HUMA should we consider putting out bad news to make the stock price go up?
drizz
Posted - 1 hour ago
$HUMA so now Laura buying and her ex selling - imagine sitting around that dinner table next week on turkey day 🤣🤣
briefingcom
Posted - 1 hour ago
$HUMA: Humacyte clinical results highlighting benefit of the ATEV in the repair of civilian and military arterial injuries published in JAMA Surgery https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241121080605HUMA&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
GJ_Rockabilt
Posted - 1 hour ago
$HUMA Don't forget about your more volatile HUMAW. Do your Due Diligence. Not Financial Advise.
CEOBuysDisclosures
Posted - 2 hours ago
$HUMA CEO purchased 1,797 shares at $4.44 for a total of $7,979. Niklason Laura E now owns 3,633,136 shares. https://ceo-buys.com
StayDilfy
Posted - 2 hours ago
$HUMA Someday, when this is hovering over 80, we will look back and wonder why the fuck we didn’t buy at 4.
qtip04
Posted - 2 hours ago
$HUMA if you are not convinced that AETV is the future and AETV for trauma won't be approved before Thanks giving, you better check your self. LFG!
SkyYk2
Posted - 2 hours ago
$HUMA I think approval will come from the FDA soon.
Akwaba76
Posted - 2 hours ago
$HUMA super!!!
Phillvsthemarket
Posted - 2 hours ago
$HUMA all of us must TWEET Vivek and RFK this is what they are looking and fight for.
NOW 🚨
SkyYk2
Posted - 3 hours ago
$HUMA
StayDilfy
Posted - 3 hours ago
$HUMA Look at the authorship of the recent publication… fucken stacked! No damn way all these surgeons would put their name on a medical journal publication if it wasn’t revolutionary!
LawOfInertia
Posted - 3 hours ago
$HUMA Approval is in the air. Don't you feel it?
theduebromanbro
Posted - 3 hours ago
$HUMA 11:19 AM - 11:24 AM New Developments In Clinical Results After 2 Years With Tissue Engineered Human Biological Arterial Grafts (Humacyte) In Military And Civilian Studies Presenter(s): Todd E. Rasmussen, MD, FACS / Charles J. Fox, MD, FACS / Randall R. De Martino, MD Location: Grand Ballroom East 3rd Floor Today at VEITH
caedus40
Posted - 3 hours ago
$HUMA alright you're my target this payday!!! buying 500.00 worth more this morning.
filodendron
Posted - 3 hours ago
$HUMA
drizz
Posted - 3 hours ago
$HUMA this is what I believe the fda was waiting on - longer term follow up and now they have it - ok fda let’s roll!
Also published were longer-term follow-up results from the V005 and V017 studies. The ATEV was observed to be mechanically durable and does not appear to dilate or become stenotic over time. Long-term outcomes for secondary patency, limb salvage, freedom from conduit infection, and patient survival were evaluated by Kaplan-Meier analysis. The average follow-up duration for patients receiving the ATEV for extremity trauma is 334.4 days, with a total patient exposure of 61.3 years. These results showcased the potential of the ATEV to retain patency over the longer duration of follow up. No ATEV infections or patient deaths were reported after month three
theduebromanbro
Posted - 3 hours ago
$HUMA Calling all day traders, we'd like a pump please.
drizz
Posted - 3 hours ago
$HUMA In summary, researchers concluded that the 30-day outcomes in civilian and military trauma patients indicate superior secondary patency, limb salvage, and resistance to infection of the ATEV conduit compared to synthetic grafts.
"I believe that the ATEV will revolutionize vascular trauma care and be profoundly beneficial to our patients," said Rishi Kundi, MD, Chief of Vascular and Endovascular Trauma at the University of Maryland's R Adams Cowley Shock Trauma Center.
Phillvsthemarket
Posted - 3 hours ago
$HUMA I swear if I ever met someone who works at the FDA
qtip04
Posted - 3 hours ago
$HUMA This is huge, FDA wanted to see long term viability of AETV and they got it now. I guess now genuinely approval is imminent.
